^
Association details:
| Biomarker: | PD-L1 overexpression |
|---|---|
| Cancer: | Thyroid Gland Anaplastic Carcinoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Lenvima (lenvatinib) (c-KIT inhibitor, FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PDGFR α antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The lenvatinib/pembrolizumab combination induces long lasting and complete responses in patients with metastatic anaplastic or poorly differentiated thyroid carcinoma: Results from a retrospective study and first results from the prospective phase II ATLEP trial
Published date:
09/14/2020
Excerpt:
Median PFS was 17.75 mo for all pts, and 16.5 mo for ATCs, with treatment durations ranging from 1 to 40 mo….Median OS was 18.5 mo for all pts, and 17.5 mo for ATCs, with 3 ATC being alive without relapse (40, 27 and 19 mo) despite metastasized disease at treatment start. All pts with long-term (> 2 years) or CR had either increased TMB or PD-L1 TPS > 50%.
